Covaxin’s launch in U.S. to be delayed after FDA requests additional data
The Hindu
The company anticipates that data from an additional clinical trial will be required to support the submission.
In a setback to Bharat Biotech’s COVID-19 vaccine Covaxin, the U.S. Food and Drug Administration has “ recommended” Ocugen Inc, the U.S. partner of the Indian vaccine maker, to go for Biologics Licence Application (BLA) route with additional data, nixing hopes of Emergency Use Authorisation. Ocugen in a statement on Thursday announced that as recommended by the FDA,it will pursue submission of a biologics licence application (BLA) for Covaxin. BLA is a “full approval” mechanism by the FDA for drugs and vaccines.More Related News